BRPI0908889A2 - polipeptídeo omci ou polinucleotídeo que codifica o mesmo, método para tratar ou prevenir uma doença ou condição mediada por um leucotrieno ou hidroxieicosanóide em um paciente, e, composição - Google Patents

polipeptídeo omci ou polinucleotídeo que codifica o mesmo, método para tratar ou prevenir uma doença ou condição mediada por um leucotrieno ou hidroxieicosanóide em um paciente, e, composição

Info

Publication number
BRPI0908889A2
BRPI0908889A2 BRPI0908889A BRPI0908889A BRPI0908889A2 BR PI0908889 A2 BRPI0908889 A2 BR PI0908889A2 BR PI0908889 A BRPI0908889 A BR PI0908889A BR PI0908889 A BRPI0908889 A BR PI0908889A BR PI0908889 A2 BRPI0908889 A2 BR PI0908889A2
Authority
BR
Brazil
Prior art keywords
hydroxyeicosanoid
leukotriene
patient
treating
preventing
Prior art date
Application number
BRPI0908889A
Other languages
English (en)
Inventor
Miles Nunn
Pietro Roversi
Susan Lea
Original Assignee
Natural Environment Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natural Environment Res filed Critical Natural Environment Res
Publication of BRPI0908889A2 publication Critical patent/BRPI0908889A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0908889A 2008-02-05 2009-02-05 polipeptídeo omci ou polinucleotídeo que codifica o mesmo, método para tratar ou prevenir uma doença ou condição mediada por um leucotrieno ou hidroxieicosanóide em um paciente, e, composição BRPI0908889A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0802116.4A GB0802116D0 (en) 2008-02-05 2008-02-05 Treatment
PCT/GB2009/000311 WO2009098454A2 (en) 2008-02-05 2009-02-05 Treatment of diseases and conditions mediated by eicosanoids

Publications (1)

Publication Number Publication Date
BRPI0908889A2 true BRPI0908889A2 (pt) 2015-09-15

Family

ID=39204277

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908889A BRPI0908889A2 (pt) 2008-02-05 2009-02-05 polipeptídeo omci ou polinucleotídeo que codifica o mesmo, método para tratar ou prevenir uma doença ou condição mediada por um leucotrieno ou hidroxieicosanóide em um paciente, e, composição

Country Status (10)

Country Link
US (1) US20110059885A1 (pt)
EP (1) EP2254667A2 (pt)
JP (1) JP2011511632A (pt)
CN (1) CN102066412A (pt)
AU (1) AU2009211257A1 (pt)
BR (1) BRPI0908889A2 (pt)
CA (1) CA2713032A1 (pt)
GB (1) GB0802116D0 (pt)
MX (1) MX2010008353A (pt)
WO (1) WO2009098454A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
GB0906779D0 (en) * 2009-04-20 2009-06-03 Natural Environment Res Council Composition
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
EP2521562B1 (en) * 2010-01-08 2019-09-18 Volution Immuno Pharmaceuticals SA Ev576 for use in the treatment of viral infections of the respiratory tract
US8293790B2 (en) * 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
WO2014022816A2 (en) * 2012-08-03 2014-02-06 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hetre and methods of treating or preventing arthritis using same
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
GB201307082D0 (en) * 2013-04-19 2013-05-29 Dignity Sciences Ltd Pharmaceutical composition comprising 15-HETrE and methods of using the same
EP3878835A1 (en) 2013-11-15 2021-09-15 DS Biopharma Limited Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids
JP6577951B2 (ja) * 2014-01-22 2019-09-18 マックス−デルブルック−セントラム フール モレクラーレ メディツィン（エムディーシー）Ｍａｘ−Ｄｅｌｂｒｕｃｋ−Ｃｅｎｔｒｕｍ Ｆｕｒ Ｍｏｌｅｋｕｌａｒｅ Ｍｅｄｉｚｉｎ（Ｍｄｃ） 新規ｃｙｐ−エイコサノイド誘導体
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
US9873878B2 (en) * 2015-03-30 2018-01-23 University Of Louisville Research Foundation, Inc. Compositions and methods for use in treating silicosis and lung cancer
JP2018520197A (ja) 2015-07-21 2018-07-26 アフィミューン リミテッド 癌及び神経疾患の治療または予防において使用するための、１５−ｈｅｐｅを含む組成物
US9855238B2 (en) 2015-12-18 2018-01-02 Afimmune Limited Compositions comprising 15-HEPE and methods of using the same
GB201602802D0 (en) 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
WO2018193122A1 (en) 2017-04-21 2018-10-25 Volution Immuno Pharmaceuticals Sa Coversin for the treatment of autoimmune blistering diseases
KR20190138650A (ko) * 2017-04-21 2019-12-13 볼루션 이뮤노 파마슈티컬스 에스에이 반흔성 안구 염증성 장애의 치료를 위한 코버신
GB201706406D0 (en) * 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
JP2022500389A (ja) * 2018-09-10 2022-01-04 ヴォリューション イミュノ ファーマシューティカルズ エスエイ リウマチ性疾患の治療に使用するためのコバーシン
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
CN113049802B (zh) * 2021-03-23 2022-10-14 广州医科大学附属第一医院（广州呼吸中心） 一种用于评估变应原特异性免疫治疗效果的血清学标志物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650435A (en) * 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
US20030166716A1 (en) * 2001-11-06 2003-09-04 Serhan Charles N. Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
WO2003105831A1 (en) * 2002-06-14 2003-12-24 Alcon, Inc. Use of hydroxyeicosatetraenoic acid compounds to treat ophthalmic inflammatory disorders
CA2526083C (en) * 2003-06-02 2017-01-17 Evolutec Limited Complement inhibitors
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
CA2650607A1 (en) * 2006-04-28 2007-11-08 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of cardiovascular disease
WO2008029169A2 (en) * 2006-09-08 2008-03-13 Varleigh Limited Method of treating respiratory disorders

Also Published As

Publication number Publication date
GB0802116D0 (en) 2008-03-12
EP2254667A2 (en) 2010-12-01
JP2011511632A (ja) 2011-04-14
MX2010008353A (es) 2010-11-09
CN102066412A (zh) 2011-05-18
US20110059885A1 (en) 2011-03-10
WO2009098454A2 (en) 2009-08-13
WO2009098454A3 (en) 2010-06-24
CA2713032A1 (en) 2009-08-13
AU2009211257A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
BRPI0908889A2 (pt) polipeptídeo omci ou polinucleotídeo que codifica o mesmo, método para tratar ou prevenir uma doença ou condição mediada por um leucotrieno ou hidroxieicosanóide em um paciente, e, composição
BRPI0921317A2 (pt) composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero
BRPI0908503A2 (pt) partícula com um diâmetro menor que 2mm, e, composição para o tratamento de tecidos
BR112012004333A2 (pt) composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio.
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BRPI1008974A2 (pt) composto, composição farmacêutica, e, método para tratar, prevenir ou melhorar uma doença mediada com gsk-3
BRPI0915382A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio.
BR112015003332A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BRPI0916576A2 (pt) pelo menos uma entidade química, composição farmacêutica, e, método para tratar uma condição ou distúrbio.
BR112015003398A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BRPI1014824A2 (pt) composição farmacêutica em forma de dose unitária e método de tratamento, prevenção ou redução da ocorrência de uma condição em um indivíduo
BRPI1013705A2 (pt) compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
BR112012003462A2 (pt) "composto, composição farmacêutica, e, método para tratar um paciente tendo uma condição mediada pela proteína quinase."
BRPI1013984A2 (pt) composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
BRPI0821299A2 (pt) Composto, processo para preparar o mesmo, composição farmacêutica, processo para preparar a mesma, uso de um composto, e, método para tratar, ou reduzir o risco de, uma doença ou condição.
BRPI0909768A2 (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto
BRPI1004899A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou distúrbio relacionado a pi3k em um indivíduo necessitando do mesmo, método para tratar uma doença mediada por mtor, método para tratar ambas as doenças mediadas por pi3k e hdac
BRPI1006145A2 (pt) "composição e método para tratamento de diabetes".
BRPI0916985A2 (pt) composto de tetraciclina c7-fluoro substituído, composição farmacêutica que o compreende e método para o tratamento ou prevenção de uma infecção ou colonização em um paciente
BRPI0816097A2 (pt) composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição.
BRPI0919804A2 (pt) Métodos e composição para o tratemento de problemas dermatológicos e/ou condições de cabelo
BRPI0816814A2 (pt) composto, composição farmacêutica, método para tratar, prevenir ou melhorar uma doença mediada por gsk-3, uso de um composto, e, artigo de fabricação.
BRPI1013396A2 (pt) composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto.
BRPI1000030A2 (pt) métodos para tratar esclerose múltipla em um paciente, para aumentar a capacidade de caminhar, para tratar os sintomas da esclerose múltipla, e, composição.
FI20070935A (fi) Koostumus ja menetelmä puun käsittelemiseksi

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.